Closure of the tipranavir trials SPRING and TICINO

Boehringer IngelheimAfter careful consideration of the feasibility of meeting the enrolment targets for the SPRING (Safety, efficacy and pharmacokinetics of tipranavir boosted with low dose ritonavir (500mg/200mg) twice daily in 400 racially and gender diverse HIV-positive treatment-experienced population) and TICINO (safety and efficacy of tipranavir/ritonavir in treatment-experienced patients also infected with the hepatitis B or hepatitis C viruses) trials, Boehringer Ingelheim has terminated both studies.

These trials have been stopped due to poor enrolment and not to any safety or efficacy reasons. Both the EMEA and the FDA are in agreement with the decision to halt these trials.

SPRING was designed to compare the safety and efficacy of tipranavir/ritonavir in a diverse treatment-experienced male and female population. TICINO was designed to compare the safety and efficacy of tipranavir/ritonavir in treatment-experienced patients also infected with the hepatitis B or hepatitis C viruses.

The success of modern HIV treatments including nevirapine has reduced the number of patients experiencing virologic failure on their earlier regimens and the duration of treatment in any line has increased. This is excellent news for those with HIV, but it also means that the original recruitment goals for the trials, 400 patients for SPRING and a further 200 patients for TICINO, was unfeasible. These 600 patients had to demonstrate previous treatment with at least three classes of HIV therapies and show resistance to more than one protease inhibitor drug. It is estimated that both trials would need to be open for more than 15 years to accrue the patient numbers required in order to have a meaningful result.

Boehringer Ingelheim remains committed to improving HIV therapy by providing physicians and patients with innovative antiretroviral treatment options for early and late treatment lines.

Aptivus® (tipranavir), a non-peptidic protease inhibitor which works by inhibiting the viral protease (an enzyme needed to complete the HIV replication process), remains a valuable option for treatment-experienced patients, helping them achieve and sustain viral undetectability even in patients resistant to multiple protease inhibitors.

Viramune® (nevirapine) is a product of original research done at Boehringer Ingelheim and was the first member of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of anti-HIV drugs on the market.

For further information, please visit:
http://www.boehringer-ingelheim.com/hiv

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...